Vladonix
Immune / ThymicAlso known as: Thymus peptide complex
Mechanism
An oral peptide complex derived from thymus extract — similar in concept to Thymalin (Khavinson's injectable thymic peptide) but in capsule form. It restores T-cell differentiation and immune function. Part of the "Cytomax" series of oral bioregulators that don't require injection.
Technical detail
Peptide complex isolated from animal thymus tissue, containing a mixture of short peptides (primarily di-, tri-, and tetrapeptides) with thymic bioregulatory activity. Proposed mechanism mirrors Thymalin: promotes T-lymphocyte differentiation and maturation by modulating thymic epithelial cell gene expression. In aging models, restores CD4/CD8 ratio, increases T-cell proliferative response to mitogens, and normalizes thymulin levels. Oral bioavailability is a key claim — Khavinson argues these short peptides survive GI transit due to small size and resistance to proteolysis. Part of the Cytomax oral bioregulator product line.
Effects
**Immune System (Tier 2-3 — Khavinson Bioregulator):** Vladonix is a natural thymic peptide complex extracted from young animal (calf) thymus glands, developed as part of the Khavinson bioregulator system at the St. Petersburg Institute of Bioregulation and Gerontology. It is the oral capsule form of thymic bioregulator peptides (compared to injectable thymalin). Contains a standardized complex of short peptides that modulate thymic epithelial cell function, T-cell differentiation, and overall adaptive immune competence. **T-Cell Function (Tier 2-3):** Proposed effects include restoration of thymic output of naive T cells, normalization of CD4/CD8 ratios, enhancement of T-cell proliferative responses to antigens, and restoration of cytokine production profiles (shift from immunosuppressed to balanced state). Effects are claimed to be most pronounced in elderly patients with significant thymic involution. **Aging/Immunosenescence (Tier 3):** Vladonix is specifically marketed for age-related immune decline. The Khavinson theory proposes that short thymic peptides can reactivate gene expression programs in aging thymic tissue, partially reversing thymic involution and restoring immune function to more youthful levels. Clinical data comes primarily from Russian geriatric studies.
Practitioner Guide
**Standard Protocol:** - Available as oral capsules (typically 200mg capsules containing standardized thymic peptide complex) - Dose: 1-2 capsules, 1-2 times daily - Duration: 10-30 days per course - Cycle: repeat every 3-6 months (1-2 courses per year for maintenance) - Take on empty stomach (15-20 minutes before meals) for better absorption **Clinical Use:** - Primary use: age-related immune support in patients 50+ - Post-illness immune recovery - Seasonal immune optimization (pre-winter) - Chronic infection support (adjunct to primary treatment) - Often combined with other Khavinson bioregulators: crystagen (synthetic immune), endoluten (pineal/epithalon equivalent), ventfort (vascular) **Practical Considerations:** - Sourced primarily from Russia (Peptide Bioregulator brand) - Quality and standardization concerns: as a natural extract, batch-to-batch variation is possible - Not approved by FDA, EMA, or other Western regulatory agencies - For practitioners wanting thymic peptide therapy with stronger evidence: thymosin alpha-1 (Zadaxin) has far more clinical data - Vladonix advantage over thymalin: oral administration (no injection needed) - Vladonix disadvantage vs. thymalin: less clinical data, uncertain oral bioavailability of active peptides
Research Summary
**Tier 2 — Russian Clinical Studies:** - Khavinson et al.: multiple studies in elderly cohorts showing improvement in immune markers (T-cell counts, CD4/CD8 ratio, NK cell activity) after vladonix courses - Published primarily in Russian gerontology journals (Advances in Gerontology, Bulletin of Experimental Biology and Medicine) - Often studied as part of multi-bioregulator protocols (vladonix + other organ-specific bioregulators) **Tier 3 — Limited Western Evidence:** - No Western peer-reviewed clinical trials - Oral bioavailability of thymic peptide complex is not fully characterized by Western pharmacokinetic standards - The concept of oral peptide bioregulators is supported by evidence that di- and tripeptides can be absorbed intact via PepT1 transporter, but larger peptides in the extract may not survive GI digestion - Independent replication of Khavinson results by non-Russian laboratories is limited - Related concept: oral thymic extracts (e.g., Thymomodulin) have some Western clinical data showing immune benefits in children and elderly — suggests biological plausibility